Bristol Non Current Liabilities Total from 2010 to 2025

BMY Stock  USD 57.88  2.05  3.67%   
Bristol Myers Non Current Liabilities Total yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Total is likely to outpace its year average in 2025. During the period from 2010 to 2025, Bristol Myers Non Current Liabilities Total regression line of annual values had r-squared of  0.68 and arithmetic mean of  28,024,753,125. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
1987-12-31
Previous Quarter
53.8 B
Current Value
52.4 B
Quarterly Volatility
16.7 B
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 B, Interest Expense of 2 B or Selling General Administrative of 8.8 B, as well as many indicators such as Price To Sales Ratio of 2.95, Dividend Yield of 0.0274 or PTB Ratio of 6.94. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Bristol Myers Squibb over the last few years. It is Bristol Myers' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

Bristol Non Current Liabilities Total Regression Statistics

Arithmetic Mean28,024,753,125
Geometric Mean17,076,751,533
Coefficient Of Variation81.84
Mean Deviation21,431,972,266
Median13,980,000,000
Standard Deviation22,934,964,985
Sample Variance526012618.9T
Range60.9B
R-Value0.82
Mean Square Error182512769.5T
R-Squared0.68
Significance0.000093
Slope3,961,212,868
Total Sum of Squares7890189282.8T

Bristol Non Current Liabilities Total History

202555.1 B
202452.4 B
202343.4 B
202243.8 B
202151.4 B
202061.5 B
201959.9 B

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Total52.4 B55.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.